The in vivo antitumor activity of zanidatamab and trastuzumab was evaluated in the GXA 3054 model, a high HER2-expressing (HER2 3+; Supplementary Table 10) patient-derived human tumor xenograft (PDX) model of gastric cancer. Here, ERBB2 is linked to gastric cancer.